person

Nil D. S.

Country
Sweden
Department
Department of Neurology

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
0
Sites with multiple studies

Has run more than one trial at 0 of 6 partner sites.

Specializations

Gynecologic Oncology

Focus on advanced metastatic carcinoma of the cervix and novel immunotherapy‑chemotherapy regimens.

  • atezolizumab combined with chemotherapy
  • bevacizumab augmentation
  • Survival endpoints (PFS and OS)

Therapeutic strategies aim to extend survival in stage IVB disease.

Hematologic Oncology

Investigation of multiple myeloma treatment pathways incorporating novel drug combinations.

  • ixazomib‑based regimens
  • lenalidomide and dexamethasone
  • Minimal residual disease assessment

Emphasis on depth of response prior to autologous stem cell transplantation.

Pancreatic Cancer Surgery

Evaluation of neoadjuvant approaches for resectable pancreatic head cancer to improve postoperative outcomes.

  • Neoadjuvant chemotherapy
  • Standard surgery plus adjuvant therapy
  • Early mortality reduction

Integrates systemic therapy to enhance resection success and overall survival.

Neurodegenerative Medicine

Clinical focus on Parkinson's disease within a neurology department setting.

  • Dopaminergic pathway modulation
  • Biomarker development for disease progression
  • Therapeutic optimization trials

Targets symptom control and disease‑modifying interventions.

Medical Device Innovation

Assessment of a new oral dispensing system for flexible medication delivery.

  • OraFID dispenser usability
  • Digital app integration
  • Patient adherence monitoring

Seeks to enhance patient experience and adherence to prescribed regimens.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.